Search results
Genetic profile may predict best response to weight-loss drug Wegovy - BusinessWorld Online
BusinessWorld· 7 days agoCertain genes may identify patients with obesity who are most likely to respond strongly to Novo Nordisk’s weight-loss drug Wegovy, researchers reported on Monday. The study ...
Victims of UK's infected blood scandal to start receiving final compensation payments this year
Associated Press via Yahoo News· 6 days agoOfficials announced the compensation plans a day after the publication of a report that found civil...
UK infected blood scandal victims to receive final compensation this year
Al Jazeera· 5 days agoOfficials announced the compensation plans on Tuesday, a day after the publication of a report that...
Genetic profile may predict best response to weight-loss drug Wegovy
KSL Salt Lake City· 7 days agoCertain genes may identify patients with obesity who are most likely to respond strongly to Novo...
UK to distribute final compensation payments for victims of deadly infected blood scandal
Fox News· 5 days agoVictims of the U.K.'s infected blood scandal will receive final compensation payments this year. The...
More Weight Loss With Anti-Obesity Meds and Hormone Therapy?
Medscape· 4 days agoPostmenopausal women who receive hormone therapy show significantly greater weight loss when treated...
...Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable...
Digital Journal· 3 days agoPoster highlights durable disease stabilization lasting beyond treatment completionResults suggest a unique, multimodal mechanism of action that differs from other cancer therapeuticsFavorable tolerability sets stage for Part 3 (dose optimization) of
Add-On Dupilumab for COPD Backed by Second Phase III Trial
MedPage Today· 6 days agoAdding dupilumab (Dupixent) to triple therapy reduced exacerbations and improved lung function for...
Finding Undiagnosed Asthma, COPD and Treating It Shows Benefit in Trial
MedPage Today· 7 days agoThe study first identified more than 500 adults with undiagnosed asthma or COPD via targeted...
Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at...
Benzinga· 6 days agoDupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM NOTUS results confirm landmark data from the phase 3 BOREAS study and show Dupixent significantly